Zymeworks Inc. — Earnings Quality Grade F
ZYME · Healthcare
Major red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 16 days, change -251 days YoY
AR growth -91.7% vs revenue growth 38.9%
Revenue 38.9%, CFFO 70.0%. Cash follows revenue
Expense Quality
No material inventory
CapEx growth -23.3% vs revenue 38.9%. Normal
Insufficient data
Insufficient data
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
FCF is negative ($-0.0B)
Accruals ratio = -13.9%. Low accruals
Cash $0.2B covers debt $0.0B
Balance Sheet Health
Goodwill+Intangibles $0.0B = 5% of equity. Manageable
Debt/EBITDA = -0.2x. Healthy
Other assets -25.2% vs revenue 38.9%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
Goodwill+Intangibles change -19% YoY. Normal
Manipulation Score
Insufficient data
Portfolio monitoring
Monitor ZYME continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25